Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment
NCT06655454Phase 2Recruiting
- Sponsor
- New York University
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of bupivacaine in irreversible pulpitis (3 arms), sponsored by New York University. Primary endpoint: Quality of life (OHIP-14) at Day 4. Started Nov 2024; status: recruiting.
02
Drugs
bupivacaine
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on NCT06655454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655454.